Natural cell-mediated cytotoxicity was studied in 24 patients with cutaneous T -cell lymphomas and in 18 ageand sex-matched controls studied concomitantly. Percent cytotoxicity was determined by 4-h 5 1 Cr release assay using K562 targets at effector to target ratios of 100:1, 50:1, and 25:1. Mean percent cytotoxicity was significantly lower in patients than in controls at an Manuscript r
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Immune disturbances have been associated with cutaneous T-cell lymphomas (CTCL). Several studies have reported alterations in cellular [1] [2] [3] [4] [5] a nd humoral [6] [7] [8] immunity, although some of the data are inconclusive. Recently, cells mediating antibody-dependent cellular cytotoxicity (ADCC) and natural killer (NK) cells have been gaining attention because of their role in natural host defense mechanisms. Investigation of ADCC in patients with CTCL showed that ADCC was decreased in Sezary syndrome, but normal in mycosis fungoides, suggesting impairment may correlate with severity of disease [9] . In the present study we determined NK activity in patients with various stages of CTCL and compared this to age-and sex-matched controls tested concomitantly. Since zinc deficiency h as been found in various malignancies [10] , and may result in reduced NK activity [11] , we also analyzed blood zinc and copper levels at the time of study.
MATERIALS AND METHODS

Patients and Controls
Twenty-fow· patients (16 males and eight females) with histologically confirmed CTCL were studied. Patients ranged in age from 30 to 78 years (mean, 59.9) and duration of disease !'rom time of diagnosis ranged fro m 1 week to 13 years (mean, 3 years). E leven patients had received no t herapy for at least 1 month prior to study, 3 of whom had never been treated; 10 were receiving local therapy (topical mechlorethamine
After obtaining informed consent, all blood samples were drawn betwee n 9:00-10:00 AM.
Total Lymphocyte Count
This was derived from the total leukocyte count and differential w hite blood cell count on Wright's stained peripheral blood smears.
Isolation of Peripheral Blood Lymphocytes
Heparinized venous blood was mixed with phosphate-buffered saline and layered on a Ficoll-Hypaque gradient. After 30 min of centrifugation at 400 g, interface cells were collected, washed with Eagle's minimum essential medium (MEM), and resuspended in MEM supplemented with 10% fetal calf serum, 200 mM glu tamine, 100 JlU/ ml penicillin, and 100 jlg/ml streptomycin (MEM-FCS). In the resultant preparations, cell viability was greater than 95% by trypan blue dye exclusion.
Natural Cell·Med iated Cytotoxicity (NCMC)
Target cells were K562 cells, standard targets for NK activity, which were kindly supplied by Dr. PaulL. Black (Department of Microbiology and Immunology, Temple University Health Sciences Center, Philadelphia, Pennsylvania) . These cells were carried in vitro in MEM supplemented with 5% fetal calf serum and 200 mM glu tamine. K562 cells (5 X 10 6 ) were labeled by incubation in 0.05 mCi sodium 5 1 Crchromate (1 mCi/ml) for 1 h at 37°C, washed 3 times in MEM-FCS, and resuspended at 10 5 cells/ mi. Peripheral blood lymphocytes (100 Jll) were added to 100 Ill of target cells in 96-well V-bottom microtiter plates (Linbro Chemicals, New Haven, Connecticut ) at varying concentr ations to give effector to target cell ratios of 100:1, 50:1, and 25:1. All samples were run in triplicate. The cells were centrifuged at 40 g for 2 min, incubated at 37°C in a humidified atmosphere containing 5% C0 2 -95% air for 4 h, t hen centrifuged at 200 g for 10 min. Supernatant (100 jli) from each well was aspirated, and experimental 51 Cr release determined in a Searle gamma scintillation counter. Spontaneous release was assessed by incubating "'Cr-labeled K562 cells in media without effector cells, and in all experiments was below 10%. Total "'Cr incorporated was determined in 100 Jll of 6 1 Cr-labeled K562 cells and divided by 2. Percent cytotoxicity was calculated as fo llows:
Mean experimental release -mean spontaneous release -----------X 100 Mean total incorporated -mean spontaneous release
Blood Zinc and Copp er Levels
Blood metal levels were analyzed by anodic stripping voltammetry (ESA 2011/ PMI1014S voltammeter) . Refrigerated 100-JLI blood samples from capillary containers were placed in trace metal-fTee analysis cells, combined with 2 rinses of 50-Jll aliquots of distilled deionized water and digested to dry white residue at 200°C in 300 Jll of acid reagent (24 parts HNOa:24 parts HClO.:I part H 2S0 4 ). The acid-digested samples wer. e then reconstituted in trace metal-free buffer (1.0 formula weigh t sodium acetate-0.2 formula weight sodium chloride) and electroplated at -1170/mv for 25 min while nitrogen bubbled through the solu tions. The electrodes were subsequent ly stripped of zinc and copper while NATURAL CYTOTOXICITY IN CTCL 177 recording amperometric peak heights. Metal contents were calculated from peak h eight values obtained from concurrently run standards with corresponding concentrations of elements expressed as Jlg/ 100 ml.
RESULTS
Total lymphocyte count was significantly lower in CTCL (1393 ± 101/mm 3 ) (SEM) than in controls (2010 ± 164/ mm 3 ) (p < .01). Mean percent NCMC in CTCL (47.6 ± 3.9%) was also significantly less t han controls (59.5 ± 3.4%) at an effector to target cell ratio of 100:1 (p < .05) (Fig 1) . Likewise, decreased NK activity was present at effector to target cell ratios of 50:1 (42.1 ± 3.9% VS 53.2 ± 3.7%) and 25:1 (30.8 ± 3.8% VS 38.8 ± 3.5%), although this difference was not significant (Fig 1) . Since NK activity has been reported to be higher in males than females [12] , we analyzed our results for each sex separately. Percent cytotoxicity was 46.5 ± 5.1% in males with CTCL compared to 62.3 ± 4.1% in male controls at an effector to target cell ratio of 100:1 (p < .05) (Fig 2) . Similarly, decreased NCMC was present in males at effector to target cell ratios of 50:1 (40.6 ± 5.1% vs 56.9 ± 3.9%) (p < .05) and 25:1 (29.2 ± 4.9% vs 41.7 ± 3.6%) (p < .10), respectively. The 6 male patients with values below the mean consisted of 4 patients with intracutaneous and 2 patients with extracutaneous disease. Four patients were on no systemic chemotherapy at the time of study, while 2 had received their last dose of single agent chemotherapy 3 weeks and 1 week prior to study, respectively. Absolute lymphocyte count was below control mean in 5 of the 6 patients, and at the mean in the 1 patient whose NCMC was closest to the mean. However, NK activity in females with CTCL (48.5 ± 6.2%), was only slightly lower than female controls (53.8 ± 5.8%) at an effector to target cell ratio of 100:1 (Fig 2) . This was apparent also at effector to target cell ratios of 50:1 (43.3 ± 6.1% vs 45.8 ± 7.5%) and 25:1 (31.7 ± 5.9% vs 33.1 ± 7.7%), respectively.
Since a correlation between severity of CTCL and immunologic abnormalities has been reported [3] [4] [5] 9] , NK activity was also analyzed according to stage of CTCL. NK activity in 7 patients with extracutaneous disease (39.9 ± 9.1%) was lower than in 17 patients with only intracutaneous involvement (50.2 ± 4.1%) at an effector to target cell ratio of 100:1, but this difference was not significant. Likewise, using either the TNM staging system for CTCL or classification into premycotic, plaque, tumor, or erythroderma stages, NK activity was always lower in advanced stages of CTCL, although again this decrease was not significant.
No significant difference was observed in blood zinc levels in CTCL (51.4 ± 9.7 {lg/100 ml) and in controls (58.5 ± 10.5 {lg/ 100 ml), or in blood Cu levels in CTCL (90.7 ± 3.3 {lg/100 ml) and in controls (91.4 ± 3.5 {lg/ 100 ml). Furthermore, there was no significant correlation between zinc levels and NCMC in CTCL (r = -.2) .
DISCUSSION
The results of our study show reduced NK activity in patients with CTCL. This is not explained by the decrease in total lymphocytes in CTCL, since the same ratio of lymphocytes to target cells is used in the NCMC assay. In addition, the impairment in NK activity was not related to blood zinc levels. An attractive hypothesis might be that increased levels of thymic factor found in CTCL [13] depress NK activity, since in vitro treatment of lymphocytes with human thymosin lowered NK activity [12] . Alternatively, the decrease in NK activity might be related to treatment of CTCL. Radiation, cyclophosphamide, and steroids have all been associated with reduced NK activity [12] . Although NCMC in 13 patients who were receiving either local or systemic therapy at the time of study was lower than in 11 patients who had received no treatment for at least 1 month prior to study, the difference was not significant. However, whether impairment of NK activity .is secondary to decreased numbers of NK cells or reduced function was not assessed in this study. It is also possible that antibodies against
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NK cells may be present in the sera of patients with CTCL, similar to systemic lupus erythematosus [14] .
When NK activity was analyzed separately for males and females, the reduction in NCMC in male patients compared to male controls was significant, whereas for females the decrease in NCMC was not significant. It is possible that this apparent difference is related to the smaller number of females studied. However, it could be postulated that CTCL occurs more commonly in males than in females because of impairment of NK activity.
The depression of NK activity seen in CTCL appears to be greater in more advanced stages of CTCL. Similarly, defective cell-mediated immunity [3] [4] [5] and ADCC [9] were found to correlate with stage of disease.
Our findings are consistent with a recent letter to the editor, reporting decreased NK activity in 10 patients with CTCL [15] . In addition, NK activity was found to be significantly decreased in 59 untreated patients with malignant lymphoma (27.5% ± 19.1%) when compared to healthy controls (43.7 ± 17.3%) and patients with nonlymphoid tumors (46.3 ± 16.9%) [16] . Although the physiologic significance of this impairment is uncertain, it is possible that decreased NK activity may contribute to the development of lymphomas, including CTCL. Further studies of the mechanisms responsible for this alteration of NK activity in CTCL are indicated.
